Blueprint Medicines (BPMC) Earnings Date, Estimates & Call Transcripts → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free bpmc Stock Alerts $107.19 +0.19 (+0.18%) (As of 05/3/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 7EstimatedActual EPS (Feb. 15) -$1.82 Beat By $0.22 Consensus EPS (Feb. 15) -$2.04 Read Call TranscriptListen to Call Get Blueprint Medicines Earnings AlertsEnter your email address below to receive the latest news and earnings results for BPMC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBPMC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BPMC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. Blueprint Medicines Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243($1.89)($1.31)($1.67) Q2 20243($1.56)($0.88)($1.33) Q3 20243($1.43)($0.58)($1.14) Q4 20243($1.30)($0.34)($0.95) FY 202412($6.18)($3.11)($5.08) Q1 20252($0.93)($0.87)($0.90) Q2 20252($0.80)($0.75)($0.78) Q3 20252($0.83)($0.61)($0.72) Q4 20252($0.80)($0.43)($0.62) FY 20258($3.36)($2.66) ($3.01)BPMC Earnings Date and InformationBlueprint Medicines last issued its quarterly earnings data on February 15th, 2024. The biotechnology company reported ($1.82) earnings per share for the quarter, topping the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. Its quarterly revenue was up 85.5% on a year-over-year basis. Blueprint Medicines has generated ($4.81) earnings per share over the last year (($4.81) diluted earnings per share). Earnings for Blueprint Medicines are expected to grow in the coming year, from ($5.41) to ($2.89) per share. Blueprint Medicines has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off prior year's report dates.Read More Blueprint Medicines Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/7/2024Estimated)------- 2/15/2024Q4 2023($2.04)($1.82)+$0.22($1.82)$67.34 million$71.96 million 10/26/2023Q3 2023($2.39)($2.20)+$0.19($2.20)$50.66 million$56.57 million 8/2/2023Q2 2023($2.58)($2.19)+$0.39($2.19)$45.60 million$57.60 million 5/4/2023Q1 2023($2.66)($2.15)+$0.51($2.15)$41.85 million$63.29 million 2/16/2023Q4 2022($2.73)($2.65)+$0.08($2.65)$33.52 million$38.78 million 11/1/2022Q3 2022($2.51)($2.23)+$0.28($2.23)$43.49 million$65.98 million Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022($2.23)($2.68)($0.45)($2.68)$37.61 million$36.55 million 5/3/2022Q1 2022($1.79)($1.79)-($1.79)$39.98 million$62.70 million 2/16/2022Q4 2021($0.71)($0.99)($0.28)$3.42$104.14 million$107.00 million 10/27/2021Q3 2021($1.63)($2.00)($0.37)($2.00)$42.58 million$24.19 million 7/28/2021Q2 2021($1.77)($1.86)($0.09)($1.86)$28.57 million$27.30 million Blueprint Medicines Earnings - Frequently Asked Questions When is Blueprint Medicines's earnings date? Blueprint Medicines has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates. Learn more on BPMC's earnings history. Did Blueprint Medicines beat their earnings estimates last quarter? In the previous quarter, Blueprint Medicines (NASDAQ:BPMC) reported ($1.82) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.04) by $0.22. Learn more on analysts' earnings estimate vs. BPMC's actual earnings. How can I listen to Blueprint Medicines's earnings conference call? The conference call for Blueprint Medicines's latest earnings report can be listened to online. Listen to Conference Call How can I read Blueprint Medicines's conference call transcript? The conference call transcript for Blueprint Medicines's latest earnings report can be read online. Read Transcript How much revenue does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded annual revenue of $249.38 million. How much profit does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded net income of -$506.98 million. BPMC has generated -$4.81 earnings per share over the last four quarters. What is Blueprint Medicines's EPS forecast for next year? Blueprint Medicines's earnings are expected to grow from ($5.41) per share to ($2.89) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Apellis Pharmaceuticals Earnings Ionis Pharmaceuticals Earnings Organon & Co. Earnings Elanco Animal Health Earnings BridgeBio Pharma Earnings Cytokinetics Earnings Jazz Pharmaceuticals Earnings Madrigal Pharmaceuticals Earnings Nuvalent Earnings Alpine Immune Sciences Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings? This page (NASDAQ:BPMC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
